BOSULIF: Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML

Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.